The pall over Minnesota's medical device industry seems notably absent in the Chaska offices of Lake Region Medical.
Instead, you get the distinct sense that executives believe the company's best days lie ahead.
That's saying a lot, given that Lake Region has experienced some pretty good days during the last 50 years as a contract manufacturer riding the coattails of customers like Medtronic and St. Jude Medical.
But many of those customers are now struggling with slower growth and diminished expectations. Multiple product recalls and disclosures about improper payments to doctors have battered the industry's image, and led to a slowdown in new product approvals. Minnesota exports of medical devices have been sliding since 2009. Medtronic slashed 1,700 jobs worldwide this year, including 268 in the Twin Cities. Boston Scientific has announced plans to cut 1,400 jobs worldwide, with an undisclosed number to come from Minnesota.
Things only look to get worse in the near term. Venture financing of new companies has shriveled, and device makers face increasing pressure to show that their products improve outcomes or lower health care costs. In 2013, the industry gets hit with a 2.3 percent tax on sales -- not profits -- to help pay for the new health care reform act. An industry trade group says the tax could cost companies up to $4 billion and mean the loss of more than 10 percent, or 2,700, medical device jobs in Minnesota alone.
Lake Region hasn't been immune from these forces. The family-owned company, which has annual revenue of about $200 million, acknowledges that its business has slowed this year along with its customers. "It's been a tough year, and we're feeling it," said CEO Joe Fleischhacker.
The prudent thing might be to be prudent. Instead, Lake Region is showing that innovation and risk-taking in the medical device industry isn't dead. It's just shifting or being distributed to less obvious sources.
In Lake Region's case, that means pushing ahead with a plan to transform itself from a parts supplier to a developer and manufacturer of technologically advanced medical devices. It may be another two years before those investments begin to pay off, but Fleischhacker believes the company had no choice but to set off on a riskier course.